1141-24-8

Upstream product

• 4165-96-2 3-phenylglutaric acid 
• 1122-91-4 4-bromo-benzaldehyde 
• 141-97-9 ethyl acetoacetate 
• 869592-29-0 diethyl 2,4-diacetyl-3-(4-bromophenyl)pentanedioate 
• 110-89-4 piperidine 
• 724771-55-5 3-(4-bromo-phenyl)-pentanedioic acid diethyl ester 

Downstream Products

• 1221962-27-1 3-(4-bromophenyl)-4-(5-chloro-2-benzimidazolyl)butanoic acid monohydrochloride 
• 1420804-57-4 C₁₁H₁₅BrO₂ 
• 1137-60-6 4-(4-bromo-phenyl)-piperidine-2,6-dione 
• 348110-34-9 5-[N'-(9H-fluoren-9-ylmethoxycarbonyl)-hydrazino]-5-oxo-3-(4-bromo)-phenylpentanoic acid 
• 1137-61-7 3-(4-bromo)-phenylglutaric acid anhydride 

Relevant academic research and scientific papers

Investigation of a Photochromic Diarylethene with Electron-acceptor Attached

In this contribution, an electron acceptor attached diarylethene derivative was synthesized and fully characterized. The photochromic behavior was investigated in THF. Under exposure of UV and visible light cycles, the solution color can be switched betwe

SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of inda

From diols to lactones under aerobic conditions using a laccase/TEMPO catalytic system in aqueous medium

An efficient catalytic system to oxidize quantitatively aliphatic diols using Trametes versicolor laccase and TEMPO has been developed in aqueous medium. Oxidations have occurred in a non-stereoselective fashion but with complete regio- and/or monoselectivity, obtaining lactones with excellent purity after simple extraction. This catalytic system has been demonstrated to be scalable, compatible with the presence of a variety of functionalities, and also allowed the successful enzyme recycling using a laccase-cross-linked enzyme aggregates (CLEA) preparation.

ALLOSTERIC PROTEIN KINASE MODULATORS

The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

ALLOSTERIC PROTEIN KINASE MODULATORS

The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES

A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C1-C12 alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C1-C8 alkyl group, an optionally partially hydrogenated C6-C10 aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each Y independently represents a halogen atom, a hydroxy group, a cyano group, a C1-C6 alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C2-C6 alkylene group.

Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists

The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.

Anti-atherosclerotic diaryl compounds

The present invention is concerned with diaryl compounds of formula (l) and their use in medical therapy, particularly in the prophylaxis or treatment of a clinical condition for which an ACAT inhibitor is indicated, such as hyperlipidaema or atherosclerosis. The invention also relates to pharmaceutical compositions and processes for the preparation of compounds according to the invention. STR1